1
The case-control study included 1021 patients with severe CAD and 2791 healthy SHIP participants.
2
We investigated plasma levels of IL-10 and other pro-inflammatory cytokines in patients with MetS with or without severe CAD.
3
Methods: A randomized, prospective, placebo-controlled trial in patients with a history of severe CAD, without current ischemia, and not receiving acid reducing therapy.
4
Therefore the high mortality (overall 13.2%) in our series was exclusively due to patients suffering from severe CAD and unsuitable for revascularization.